FATE - Fate Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.02
+0.41 (+2.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.61
Open15.81
Bid15.01 x 3000
Ask16.20 x 800
Day's Range15.14 - 16.05
52 Week Range8.35 - 19.11
Volume485,807
Avg. Volume642,591
Market Cap1.042B
Beta (3Y Monthly)3.03
PE Ratio (TTM)N/A
EPS (TTM)-1.18
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development

    Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu, M.D. has joined the Company as Vice President, Clinical Development. Dr. Chu brings extensive experience in the development of cancer immunotherapies from Genentech, a member of the Roche Group, where he most recently served in Product Development Oncology as global development leader of mosunetuzumab, a full-length T cell-dependent bispecific CD20/CD3 antibody. Dr. Chu will be responsible for leading clinical development of the Company’s induced pluripotent stem cell (iPSC)-derived, cell-based cancer immunotherapy programs.

  • GlobeNewswire19 days ago

    Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient treated with FT500 successfully completed an initial safety assessment. The patient received three once weekly doses of FT500, and the treatment cycle was well-tolerated with no dose-limiting toxicities or serious adverse events reported during the initial 28-day observation period. The universal, off-the-shelf natural killer (NK) cell product candidate is the first-ever cell therapy derived from an induced pluripotent stem cell (iPSC) administered to a patient in the U.S.

  • GlobeNewswire20 days ago

    Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today presented late-breaking preclinical data highlighting the Company’s unmatched ability to mass produce uniformly engineered chimeric antigen receptor (CAR) T cells for off-the-shelf cancer immunotherapy at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia (LB-073/18: Generation of Novel Single Cell-derived Engineered Master Pluripotent Cell Line as a Renewable Source for Off-the-shelf TCR-less CAR T Cells in support of First-of-kind Clinical Trial). The Company’s proprietary approach to CAR T-cell therapy utilizes a one-time genetic modification event followed by high-throughput selection of a single gene-edited induced pluripotent stem cell (iPSC).

  • What Do Analysts Think About Fate Therapeutics, Inc.’s (NASDAQ:FATE) Earnings Trajectory?
    Simply Wall St.26 days ago

    What Do Analysts Think About Fate Therapeutics, Inc.’s (NASDAQ:FATE) Earnings Trajectory?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Fate Therapeutics, Inc.'s (NASDAQ:FATE) latest earnings update in December 2018Read More...

  • GlobeNewswirelast month

    Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss, Ph.D. has been appointed to the Company’s Board of Directors. Dr. Jooss has more than 20 years of experience in oncology and immunology research and development, and is currently the Executive Vice President of Research and Chief Scientific Officer of Gritstone Oncology, Inc., a clinical-stage biotechnology company developing next-generation cancer immunotherapies targeting tumor-specific neoantigens.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT

    Q4 2018 Fate Therapeutics Inc Earnings Call

  • Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript

    FATE earnings call for the period ending December 31, 2018.

  • GlobeNewswire2 months ago

    Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

    First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in.

  • ACCESSWIRE2 months ago

    Fate Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 5, 2019 / Fate Therapeutics, Inc. (NASDAQ: FATE) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 5, 2019 at 5:00 PM ...

  • GlobeNewswire2 months ago

    Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results

    SAN DIEGO, Feb. 28, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
    Zacks2 months ago

    Cronos (CRON) to Report Q4 Earnings: What's in the Cards?

    Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.

  • Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks2 months ago

    Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SAN DIEGO, Feb. 22, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • GlobeNewswire2 months ago

    Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation

    Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley, M.D., M.S., a leading expert in the field of natural killer (NK) cell receptor immunogenetics and in the clinical development of NK cell cancer immunotherapies, has joined the Company as Senior Vice President, Clinical Translation. Dr. Cooley brings to Fate Therapeutics more than 12 years of leadership in the field of NK cell clinical research and development, having most recently served as Associate Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota.

  • GlobeNewswire2 months ago

    Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day

    SAN DIEGO, Feb. 07, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • MarketWatch2 months ago

    Fate Therapeutics stock up 11% after FDA clears IND application

    Shares of Fate Therapeutics Inc. were up 11% in premarket trade Wednesday after the company announced that the FDA had cleared its investigational new drug application for FT516, a potential therapy for patients with certain blood cancers. FT516 is a natural killer cell product engineered to make a surface protein called the CD16 Fc receptor. CD16 is a surface receptor that helps regulate an immune response where natural killer cells bind to and kill cancer cells. Cancer patients can have reduced CD16, inhibiting their bodies' tumor-killing responses. FT516's CD16 Fc receptor has been modified so that it will not have this problem -- the idea is that administering this therapy will allow for a better anti-tumor response in cancer patients. Fate Therapeutics said its initial study of FT516 will assess the safety and tolerability of three weekly doses of the therapy to treat certain later-stage blood cancers. Shares of Fate Therapeutics have gained 8% in the year to date, while the S&P 500 has gained 9.2%.

  • GlobeNewswire2 months ago

    Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for FT516, the Company’s off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel CD16 Fc receptor. FT516 is the first-ever cell therapy derived from a genetically engineered pluripotent stem cell cleared for clinical testing in the world, and is the Company’s second off-the-shelf, iPSC-derived NK cell product candidate cleared for clinical investigation by the FDA within the past two months.

  • Why Fate Therapeutics, Inc.’s (NASDAQ:FATE) CEO Pay Matters To You
    Simply Wall St.3 months ago

    Why Fate Therapeutics, Inc.’s (NASDAQ:FATE) CEO Pay Matters To You

    J. Wolchko became the CEO of Fate Therapeutics, Inc. (NASDAQ:FATE) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...

  • Vanda Pharmaceuticals: Recent Developments and Analyst Ratings
    Market Realist4 months ago

    Vanda Pharmaceuticals: Recent Developments and Analyst Ratings

    On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.

  • Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up
    Insider Monkey4 months ago

    Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • GlobeNewswire5 months ago

    Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new preclinical data on the Company’s induced pluripotent stem cell (iPSC) product platform and its iPSC-derived, off-the-shelf cell-based cancer immunotherapy pipeline at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition. Last week, the Company announced that the U.S. Food and Drug Administration (FDA) allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master iPSC line.

  • GlobeNewswire5 months ago

    Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products

    Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has secured an exclusive option to an intellectual property portfolio owned by the Max Delbrück Center for Molecular Medicine (MDC) covering novel humanized chimeric antigen receptor (CAR) constructs that uniquely and specifically bind B-cell Maturation Antigen (BCMA). Under the agreement with MDC, Fate Therapeutics holds an exclusive option to exclusively license the portfolio for all cell products, including CAR NK- and T-cell products, derived from induced pluripotent stem cells (iPSCs).

  • Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
    Zacks5 months ago

    Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%

    Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • GlobeNewswire5 months ago

    Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.